PHLDA1 promotes microglia-mediated neuroinflammation via regulating K63-linked ubiquitination of TRAF6

Chaojun Han1, Pengju Yan1, Tao He1

  • 1Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu 215123, China; College of Pharmaceutical Sciences and the Collaborative Innovation Center for Brain Science, Soochow University, Suzhou, China.

Insights

Pleckstrin homology-like domain family A member 1 (PHLDA1) drives neuroinflammation in Parkinson's disease models. Inhibiting PHLDA1 reduces inflammation and motor deficits, suggesting PHLDA1 as a potential therapeutic target.

Area of Science:

  • Neuroscience
  • Immunology
  • Molecular Biology

Background:

  • Microglia-driven neuroinflammation is central to neurodegenerative diseases like Parkinson's disease (PD).
  • Pleckstrin homology-like domain family A member 1 (PHLDA1) is implicated in immune regulation, particularly Toll-like receptor signaling.

Purpose of the Study:

  • To investigate the role of PHLDA1 in microglia-mediated inflammation and neuronal protection.
  • To determine if PHLDA1 is a potential therapeutic target for Parkinson's disease.

Main Methods:

  • Studied PHLDA1 expression in microglia in response to inflammatory stimuli in vitro and in vivo.
  • Utilized adeno-associated virus serotype (AAV) to knock down PHLDA1 in a mouse model of Parkinson's disease (MPTP-induced).
  • Assessed neuroinflammation markers (TNF-α, IL-1β, iNOS, COX-2) and NF-κB signaling pathway activation.

Main Results:

  • PHLDA1 expression increased rapidly in microglia upon inflammatory stimulation.
  • PHLDA1 knockdown ameliorated MPTP-induced motor deficits and reduced neuroinflammation in mice.
  • PHLDA1 deficiency decreased pro-inflammatory gene expression and interfered with TRAF6 ubiquitination and NF-κB activation.

Conclusions:

  • PHLDA1 is a key modulator of microglial inflammatory responses and dopaminergic neurotoxicity.
  • PHLDA1 inhibition represents a potential therapeutic strategy for neuroinflammation-related diseases, including Parkinson's disease.